Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG002 in HER2-positive Advanced Urothelial Cancer
NCT04839510Phase 2Unknown
- Sponsor
- Hangzhou Miracogen
- Start
- Apr 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MRG002 in urothelial carcinoma (UC), sponsored by Hangzhou Miracogen. Status: unknown.
02
Drugs
MRG002
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04839510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04839510.